platoseedplatoseed
The next generation of induced-proximity medicines.
General Proximity aims to advance proximity-based medicines by building a generalized, mechanism-agnostic proximity discovery engine to develop highly efficacious proximity therapeutics. The company positions proximity as a master regulator of biology and targets previously undruggable proteins.
The company has built an unbiased effector discovery platform to identify the most powerful proximity mechanisms for a given target, enabling development of proximity therapeutics that modulate a target protein’s function through its proximity relationships with effector proteins. Their approach leverages the concept of the ‘effectome’ and proximity events to drive downstream biological modulation, with collaborations and programs aimed at targets beyond traditional modalities.
Who it’s for: Biotech/Pharma companies, research institutions, and therapeutic developers focused on difficult-to-drug targets and proximity-based mechanisms.
Hiring/careers presence (Join Us), active collaboration with leading institutions, investor backing and grants, multiple listed programs and a track record of publications and patents
Armand completed his PhD in Chemical Biology at the Scripps Research Institute under the supervision of Dr. Benjamin F. Cravatt. There he co-authored 19 scientific publications in prestigious journals such as Cell, Nature, and Science, as well as multiple patents, including a portion of the foundational IP for Abide Therapeutics (acq. Lundbeck) and Vividion Therapeutics (acq. Bayer). Prior to founding GP he was an early employee at the Flagship Pioneering start-up Inzen Tx (now Sonata).
Formerly “Weatherwax Bio” · why startups rename →
Multi-targeted therapeutics to treat complex diseases
Combining 3D cell culture & AI to translate drugs to clinical success
